Evidence map›Paper›PMID 41924551›Full record

ReviewDrug design, development and therapy2026

Key Considerations for Targeting

Cody Eslinger, Mohamad Bassam Sonbol, Ben George, Hani Babiker, Mitesh J Borad, Tanios S Bekaii-Saab

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Cody EslingerDepartment of Hematology-Oncology, Mayo Clinic, Phoenix, AZ, USA.ORCID 0000-0002-8057-0841
Mohamad Bassam SonbolDepartment of Hematology-Oncology, Mayo Clinic, Phoenix, AZ, USA.ORCID 0000-0002-6931-242X
Ben GeorgeDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Hani BabikerDepartment of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA.
Mitesh J BoradDepartment of Hematology-Oncology, Mayo Clinic, Phoenix, AZ, USA.
Tanios S Bekaii-SaabDepartment of Hematology-Oncology, Mayo Clinic, Phoenix, AZ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal solid malignancies, characterized by aggressive biology and a paucity of effective treatments. Activating mutations in

Indexed as

Antineoplastic AgentsCarcinoma, Pancreatic DuctalPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)AnimalsHumansMolecular Targeted TherapyMutationAntineoplastic AgentsKRAS protein, humanProto-Oncogene Proteins p21(ras)chemotherapyKRASnext generation sequencingpancreatic cancertargeted therapy

Identifiers

PMID41924551
PMCPMC13037533

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.